DOYLESTOWN, PA — In a significant stride toward advancing cancer treatment, Antennova, a clinical-stage biotechnology firm dedicated to oncology, has announced the successful completion of the first dosing cohort in its Phase I study of ATN-031, an innovative anti-CD24 antibody. This trial, named the PERFORM trial, is focused on patients with advanced solid tumors or B-cell non-Hodgkin’s lymphoma (B-NHL) and represents a pioneering effort in the U.S. to explore the therapeutic potential of targeting CD24 in late-stage cancer patients.
The PERFORM trial, led by prestigious institutions including The University of Texas MD Anderson Cancer Center, has enrolled five late-stage cancer patients under a Bayesian Optimal Interval (BOIN) design. Notably, no dose-limiting toxicities (DLTs) have been reported among these patients, and tumor shrinkage was observed in one patient who had previously undergone seven lines of therapy, indicating early clinical activity of ATN-031 in this heavily pre-treated group.
Jay Mei, M.D., Ph.D., Founder and Chairman of the Board of Antennova, expressed gratitude to the patients and study centers participating in the trial and optimism about the early signs of clinical efficacy. “Introducing the first anti-CD24 program for late-stage cancer patients in the U.S. is a very important milestone for Antennova,” he said, highlighting the company’s commitment to advancing cancer treatment through innovation.
The PERFORM trial is a first-in-human, multi-center, open-label study designed to evaluate the safety and tolerability of ATN-031 as a monotherapy, determine the appropriate dose for Phase II studies, characterize the pharmacology, evaluate immunogenicity, and assess preliminary efficacy. This trial stands as a crucial step in understanding how targeting CD24 with ATN-031 can benefit patients with advanced solid tumors or B-NHL, offering new hope in the fight against cancer.
The significance of this trial extends beyond the immediate results. By focusing on a novel target like CD24, which plays a role in cancer cell proliferation and metastasis, Antennova is exploring uncharted territory in oncology research. The successful completion of the first dosing cohort without any DLTs and the observed tumor shrinkage in a heavily pre-treated patient underscore the potential of ATN-031 as a groundbreaking treatment option.
As the trial progresses, the oncology community and industry watchers are keenly awaiting further updates and presentations at major international medical conferences. The early successes of the PERFORM trial could signal a paradigm shift in cancer treatment, emphasizing the importance of targeted therapies in managing complex diseases. With continued research and development, Antennova’s work may pave the way for more effective and personalized cancer treatments, reinforcing the company’s role at the forefront of oncological innovation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.